Tom Huang

Director, Process Development and MSAT, Nkarta, Inc. (cell therapy process development and scale-up to support GMP manufacturing and CMC, cancer and autoimmune disease treatments), 2021 to Present; Associate Director, Allogene Therapeutics, 2019 to 2021; Director, AbSci, 2017 to 2019; Associate Principal Scientist, Merck, 2015 to 2017; Principal Investigator, Panorama Research Inc., 2011 to 2015. Previously, cell culture and fermentation process development: 5 INDs in immunotherapy and cell therapy programs. Expertise in bioprocess and bioproduct development, innovation, R&D strategy, team management, and entrepreneurship.

Tom has accumulated 8 patents or patent applications, contributed to 12 peer-reviewed journal publications, and successfully initiated and secured numerous research grants from NIH, NSF, and USDA.